In a huPBL-NSG mouse model using human prostate cancer cells, TIL therapy demonstrated a predominance of CD8 + T cells with increased CD69 and CD56 expression, resulting in slowed tumor growth but not complete elimination, highlighting the model’s relevance for preclinical studies of tumor immune interactions [85]. The gene discussed is CD8A; the disease is neoplasm.